Zafgen Inc (ZFGN):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Zafgen Inc (ZFGN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C7568
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:57
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Zafgen Inc (Zafgen) is a clinical-stage biopharmaceutical company that develops transformative therapies for patients affected by a range of metabolic diseases. Its pipeline product portfolio includes ZGN-1061, a small molecule MetAP2 inhibitor being developed for patients with type 2 diabetes; ZGN-1258 is designed to change the way the body metabolizes fat, reduce fat mass, and decrease hyperphagia, for the treatment of Prader-Willi syndrome (PWS). Zafgen has developed several MetAP2 inhibitors, which modulate the cellular mechanisms that control the body’s ability to make and store fat and glucose. The company operates through academic institutions, other companies and research organizations for the development of therapeutic drugs against rare complex metabolic disorders. Zafgen is headquartered in Boston, Massachusetts, the US.

Zafgen Inc (ZFGN) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Zafgen Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Zafgen Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Zafgen Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Zafgen Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Zafgen Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Zafgen Inc, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
Zafgen Raises US$45 Million In Series E Financing Round 11
Zafgen Raises US$21 Million In Series D Financing 13
Zafgen Raises US$3 Million In Venture Financing 15
Partnerships 16
ZappRx Enters into Agreement with Zafgen 16
Equity Offering 17
Zafgen Raises USD69 Million in Public Offering of Shares 17
Zafgen Raises USD138 Million in Public Offering of Shares 19
Zafgen Raises USD110.4 Million in IPO 21
Zafgen Inc – Key Competitors 23
Zafgen Inc – Key Employees 24
Zafgen Inc – Locations And Subsidiaries 25
Head Office 25
Other Locations & Subsidiaries 25
Recent Developments 26
Financial Announcements 26
Aug 07, 2018: Zafgen announces second quarter 2018 financial results 26
May 08, 2018: Zafgen Announces First Quarter 2018 Financial Results 29
Mar 06, 2018: Zafgen Reports Fourth Quarter and Full Year 2017 Financial Results 31
Nov 07, 2017: Zafgen Reports Third Quarter 2017 Financial Results 33
Aug 08, 2017: Zafgen Reports Second Quarter 2017 Financial Results 35
May 09, 2017: Zafgen Reports First Quarter 2017 Financial Results 37
Mar 09, 2017: Zafgen Reports Fourth Quarter And Full Year 2016 Financial Results 38
Corporate Communications 39
Aug 02, 2018: Zafgen announces departure of President and Chief Scientific Officer Dr. Thomas Hughes 39
Jun 25, 2018: Zafgen set to join Russell 3000 index 40
Jun 07, 2018: Zafgen Appoints Industry Veteran And Healthcare Policy Expert Dr. Wendy Everett To Its Board Of Directors 41
May 30, 2018: Zafgen Appoints Brian Mcveigh As Chief Business Officer 42
Oct 10, 2017: Zafgen Appoints Jeffrey Hatfield as Chief Executive Officer; Thomas Hughes, Ph.D. to Continue as President, Appointed Chief Scientific Officer 43
Clinical Trials 44
Jun 25, 2018: Zafgen to Host ZGN-1061 Phase 2 Data Conference Call 44
Jun 23, 2018: Zafgen Announces Positive Full Results in Phase 2 Proof-of-Concept Trial of ZGN-1061 in Patients with Difficult-to-Control Type 2 Diabetes 45
Mar 06, 2018: Zafgen Announces Positive Interim Data from Ongoing ZGN-1061 Phase 2 Proof-of-Concept Trial in Patients with Type 2 Diabetes 47
Jan 05, 2018: Zafgen Provides Update on its Obesity Drug candidate ZGN-1061 48
Sep 12, 2017: Zafgen Initiates Phase 2 Clinical Trial for ZGN-1061 in Patients with Type 2 Diabetes 49
Sep 12, 2017: Zafgen Presents New Preclinical Data on ZGN-1061 at the 53rd Annual Meeting of the European Association for the Study of Diabetes 50
Jun 10, 2017: Zafgen Presents New Data Highlighting Potential of ZGN-1061 for the Treatment of Type 2 Diabetes and Obesity at the American Diabetes Association’s 77th Annual Scientific Sessions 51
Jun 06, 2017: Zafgen to Present Two Late-Breaking Abstracts for ZGN-1061 at the American Diabetes Association 77th Scientific Sessions 53
May 04, 2017: Zafgen Announces Positive Topline Phase 1 Data for ZGN-1061, a Second Generation MetAP2 Inhibitor 54
Mar 09, 2017: Zafgen Provides Update on ZGN-1061 56
Appendix 57
Methodology 57
About GlobalData 57
Contact Us 57
Disclaimer 57

List of Tables
Zafgen Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Zafgen Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Zafgen Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Zafgen Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Zafgen Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Zafgen Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Zafgen Raises US$45 Million In Series E Financing Round 11
Zafgen Raises US$21 Million In Series D Financing 13
Zafgen Raises US$3 Million In Venture Financing 15
ZappRx Enters into Agreement with Zafgen 16
Zafgen Raises USD69 Million in Public Offering of Shares 17
Zafgen Raises USD138 Million in Public Offering of Shares 19
Zafgen Raises USD110.4 Million in IPO 21
Zafgen Inc, Key Competitors 23
Zafgen Inc, Key Employees 24
Zafgen Inc, Other Locations 25

List of Figures
Zafgen Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Zafgen Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Zafgen Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Zafgen Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Zafgen Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Zafgen Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Zafgen Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★海外企業調査レポート[Zafgen Inc (ZFGN):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Kongsberg Maritime AS-石油・ガス分野:企業M&A・提携分析
    Summary Kongsberg Maritime AS (Kongsberg Maritime), a subsidiary of Kongsberg Gruppen AS, is a provider of merchant marine, subsea and offshore solutions. The company offers a wide range of products that include bridge systems, camera systems, deck systems, engine room and automation systems, inform …
  • Insightra Medical Inc-医療機器分野:企業M&A・提携分析
    Summary Insightra Medical Inc (Insightra Medical), a subsidiary of GPB Life Science Holdings LLC is a medical device company that develops disposable devices. The company offers cardiovascular and surgical solutions. Its cardiovascular solutions include Ultra 7FR IAB and modulare. The Modulare Cathe …
  • Esso (Thailand) PCL (ESSO):企業の財務・戦略的SWOT分析
    Esso (Thailand) PCL (ESSO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • FMC Corporation:企業の戦略・SWOT・財務情報
    FMC Corporation - Strategy, SWOT and Corporate Finance Report Summary FMC Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • IntriCon Corp (IIN):医療機器:M&Aディール及び事業提携情報
    Summary IntriCon Corp (IntriCon) is a designer, developer and manufacturer of miniature and micro-miniature body-worn medical and electronics products. The company’s products comprise glucose monitoring, medical coils, cardiac monitoring, amplifiers, systems, plastic medical molding, support product …
  • PJSC Detsky Mir (DSKY):企業の財務・戦略的SWOT分析
    PJSC Detsky Mir (DSKY) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • Inform Diagnostics Inc:医療機器:M&Aディール及び事業提携情報
    Summary Inform Diagnostics Inc(Inform Diagnostics) formerly known as Miraca Life Sciences, a subsidiary of Miraca Holdings Inc, is an anatomic pathology laboratory that offers diagnostic services. The laboratory provides services in the areas of breast health, dermatology, gastroenterology, hematolo …
  • Martifer SGPS SA (MAR)-エネルギー分野:企業M&A・提携分析
    Summary Martifer SGPS S.A. (Martifer) is an industrial holding company. Through its subsidiaries, the company provides construction services to metal mechanical structures, aluminum and glass facades, and infrastructure facilities. It promotes and develops renewable energy projects in the wind secto …
  • George Weston Limited (WN):企業の財務・戦略的SWOT分析
    George Weston Limited (WN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • Centauri Therapeutics Ltd:製薬・医療:M&Aディール及び事業提携情報
    Summary Centauri Therapeutics Ltd (Centauri Therapeutics) is a biotechnology company that discovers and develops novel molecules for life threatening diseases. The company uses alphamer technology to develop anti-infective therapeutics. Its alphamer technology is based on programmable immunity in wh …
  • Bank of China Ltd:企業のM&A・事業提携・投資動向
    Bank of China Ltd - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Bank of China Ltd Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), div …
  • Texas Children’s Hospital:企業の戦略的SWOT分析
    Texas Children's Hospital - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • Valensa International LLC:企業の戦略・SWOT・財務分析
    Valensa International LLC - Strategy, SWOT and Corporate Finance Report Summary Valensa International LLC - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • Isramco Inc (ISRL):企業の財務・戦略的SWOT分析
    Summary Isramco Inc (Isramco), a subsidiary of Israel Oil Company Ltd, is an oil and gas company that offers exploration, production and development of oil and natural gas properties. The company acquires, explores, develops and produces oil and natural gas resources. It offers services such as work …
  • Y.S.P. Southeast Asia Holding Berhad (YSPSAH):企業の財務・戦略的SWOT分析
    Y.S.P. Southeast Asia Holding Berhad (YSPSAH) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key stre …
  • Cara Therapeutics Inc (CARA):医療機器:M&Aディール及び事業提携情報
    Summary Cara Therapeutics Inc (Cara Therapeutics) is a biotechnology company that develops and commercializes chemical entities for acutepain, chronic pain and pruritus. The company offers kappa opioid receptor agonists in the therapeutic areas of acute pain, chronic pain, neuropathic pain and pruri …
  • BreitBurn Energy Partners L.P. (BBEP)-石油・ガス分野:企業M&A・提携分析
    Summary BreitBurn Energy Partners L.P. (BreitBurn Energy) is an independent upstream oil and gas partnership company that acquires assets, and explores, develops and produces oil and gas properties in the US. The company’s asset portfolio consist of producing and non-producing oil, Natural Gas Liqui …
  • Gilead Sciences Inc (GILD):企業の財務・戦略的SWOT分析
    Gilead Sciences Inc (GILD) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • Oswaldo Cruz Foundation:製薬・医療:M&Aディール及び事業提携情報
    Summary Oswaldo Cruz Foundation (Oswaldo Cruz) is a provider of research and development in biological sciences. It offers research programs and technological development projects in vaccines production, medications, drugs, reagents and diagnostic kits. The foundation provides research in experiment …
  • HOB Biotech Group Suzhou Co Ltd:医療機器:M&Aディール及び事業提携情報
    Summary HOB Biotech Group Suzhou Co Ltd (HOB Biotech) is a manufacturer of allergy and autoimmune in vitro diagnostics. It owns and operates bioclia, bioline, and biolisa. The company’s bioclia is engaged in cutting-edge nanoparticle and chemiluminescent technology, and chemiluminescent immuno assay …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆